Adenosine signaling contributes to ethanol-induced fatty liver in mice.

Fatty liver is commonly associated with alcohol ingestion and abuse. While the molecular pathogenesis of these fatty changes is well understood, the biochemical and pharmacological mechanisms by which ethanol stimulates these molecular changes remain unknown. During ethanol metabolism, adenosine is generated by the enzyme ecto-5'-nucleotidase, and adenosine production and adenosine receptor activation are known to play critical roles in the development of hepatic fibrosis. We therefore investigated whether adenosine and its receptors play a role in the development of alcohol-induced fatty liver. WT mice fed ethanol on the Lieber-DeCarli diet developed hepatic steatosis, including increased hepatic triglyceride content, while mice lacking ecto-5'-nucleotidase or adenosine A1 or A2B receptors were protected from developing fatty liver. Similar protection was also seen in WT mice treated with either an adenosine A1 or A2B receptor antagonist. Steatotic livers demonstrated increased expression of genes involved in fatty acid synthesis, which was prevented by blockade of adenosine A1 receptors, and decreased expression of genes involved in fatty acid metabolism, which was prevented by blockade of adenosine A2B receptors. In vitro studies supported roles for adenosine A1 receptors in promoting fatty acid synthesis and for A2B receptors in decreasing fatty acid metabolism. These results indicate that adenosine generated by ethanol metabolism plays an important role in ethanol-induced hepatic steatosis via both A1 and A2B receptors and suggest that targeting adenosine receptors may be effective in the prevention of alcohol-induced fatty liver.

Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors

Dopamine D1, dopamine D2, and adenosine A2A receptors are highly expressed in striatal medium-sized spiny neurons. We have examined, in vivo, the influence of these receptors on the state of phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32). DARPP-32 is a potent endogenous inhibitor of protein phosphatase-1, which plays an obligatory role in dopaminergic transmission. A dose-dependent increase in the state of phosphorylation of DARPP-32 occurred in mouse striatum after systemic administration of the D2 receptor antagonist eticlopride (0.1–2.0 mg/kg). This effect was abolished in mice in which the gene coding for the adenosine A2A receptor was disrupted by homologous recombination. A reduction was also observed in mice that had been pretreated with the selective A2A receptor antagonist SCH 58261 (10 mg/kg). The eticlopride-induced increase in DARPP-32 phosphorylation was also decreased by pretreatment with the D1 receptor antagonist SCH 23390 (0.125 and 0.25 mg/kg) and completely reversed by combined pretreatment with SCH 23390 (0.25 mg/kg) plus SCH 58261 (10 mg/kg). SCH 23390, but not SCH 58261, abolished the increase in DARPP-32 caused by cocaine (15 mg/kg). The results indicate that, in vivo, the state of phosphorylation of DARPP-32 and, by implication, the activity of protein phosphatase-1 are regulated by tonic activation of D1, D2, and A2A receptors. The results also underscore the fact that the adenosine system plays a role in the generation of responses to dopamine D2 antagonists in vivo.

Modulation of GABA and glutamate release by brain-derived neurotrophic factor : role of adenosine A2A receptors

Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2014

Latent N-methyl-D-aspartate receptors in the recurrent excitatory pathway between hippocampal CA1 pyramidal neurons: Ca(2+)-dependent activation by blocking A1 adenosine receptors.

When performed at increased external [Ca2+]/[Mg2+] ratio (2.5 mM/0.5 mM), temporary block of A1 adenosine receptors in hippocampus [by 8-cyclopentyltheophylline (CPT)] leads to a dramatic and irreversible change in the excitatory postsynaptic current (EPSC) evoked by Schaffer collateral/commissural (SCC) stimulation and recorded by in situ patch clamp in CA1 pyramidal neurons. The duration of the EPSC becomes stimulus dependent, increasing with increase in stimulus strength. The later occurring component of the EPSC is carried through N-methyl-D-aspartate (NMDA) receptor-operated channels but disappears under either the NMDA antagonist 2-amino-5-phosphonovaleric acid (APV) or the non-NMDA antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX). These findings indicate that the late component of the SCC-evoked EPSC is polysynaptic: predominantly non-NMDA receptor-mediated SCC inputs excite CA1 neurons that recurrently excite each other by predominantly NDMA receptor-mediated synapses. These recurrent connections are normally silent but become active after CPT treatment, leading to enhancement of the late component of the EPSC. The activity of these connections is maintained for at least 2 hr after CPT removal. When all functional NMDA receptors are blocked by dizocilpine maleate (MK-801), subsequent application of CPT leads to a partial reappearance of NMDA receptor-mediated EPSCs evoked by SCC stimulation, indicating that latent NMDA receptors are recruited. Altogether, these findings indicate the existence of a powerful system of NMDA receptor-mediated synaptic contacts in SCC input to hippocampal CA1 pyramidal neurons and probably also in reciprocal connections between these neurons, which in the usual preparation are kept latent by activity of A1 receptors.

Development of small molecular tools for the cellular study of adenosine receptors

The adenosine receptors are members of the G-protein coupled receptor (GPCR) family which represents the largest class of cell-surface proteins mediating cellular communication. As a result, GPCRs are formidable drug targets and it is estimated that approximately 30% of the marketed drugs act through members of this receptor class. There are four known subtypes of adenosine receptors: A1, A2A, A2B and A3. The adenosine A1 receptor, which is the subject of this presentation, mediates the physiological effects of adenosine in various tissues including the brain, heart, kidney and adipocytes. In the brain for instance, its role in epilepsy and ischemia has been the focus of many studies. Previous attempts to study the biosynthesis, trafficking and agonist-induced internalisation of the adenosine A1 receptor in neurons using fluorescent protein-receptor fusion constructs have been hampered by the sheer size of the fluorescent protein (GFP) that ultimately affected the function of the receptor. We have therefore initiated a research programme to develop small molecule fluorescent agonists that selectively activate the adenosine A1 receptor. Our probe design is based on the endogenous ligand adenosine and the known unselective adenosine receptor agonist NECA. We have synthesised a small library of non-fluorescent adenosine derivatives that have different cyclic and bicyclic moieties at the 6 position of the purine ring and have evaluated the pharmacology of these compounds using a yeast-based assay. This analysis revealed compounds with interesting behaviour, i.e. exhibiting subtype-selectivity and biased signalling, that can be potentially used as tool compounds in their own right for cellular studies of the adenosine A1 receptor. Furthermore, we have also linked fluorescent dyes to the purine ring and discovered fluorescent compounds that can activate the adenosine A1 receptor.

Adenosine activates ATP-sensitive potassium channels in arterial myocytes via A2 receptors and cAMP-dependent protein kinase.

The mechanism by which the endogenous vasodilator adenosine causes ATP-sensitive potassium (KATP) channels in arterial smooth muscle to open was investigated by the whole-cell patch-clamp technique. Adenosine induced voltage-independent, potassium-selective currents, which were inhibited by glibenclamide, a blocker of KATP currents. Glibenclamide-sensitive currents were also activated by the selective adenosine A2-receptor agonist 2-p-(2-carboxethyl)-phenethylamino-5'-N- ethylcarboxamidoadenosine hydrochloride (CGS-21680), whereas 2-chloro-N6-cyclopentyladenosine (CCPA), a selective adenosine A1-receptor agonist, failed to induce potassium currents. Glibenclamide-sensitive currents induced by adenosine and CGS-21680 were largely reduced by blockers of the cAMP-dependent protein kinase (Rp-cAMP[S], H-89, protein kinase A inhibitor peptide). Therefore, we conclude that adenosine can activate KATP currents in arterial smooth muscle through the following pathway: (i) Adenosine stimulates A2 receptors, which activates adenylyl cyclase; (ii) the resulting increase intracellular cAMP stimulates protein kinase A, which, probably through a phosphorylation step, opens KATP channels.

Adenosine Modulatesa alpha(2)-Adrenergic Receptors within Specific Subnuclei of the Nucleus Tractus Solitarius in Normotensive and Spontaneously Hypertensive Rats

Adenosine Is known to modulate neuronal activity within the nucleus tractus solitarius (NTS). The modulatory effect of adenosine A, receptors (A(1R)) on alpha(2)-adrenoceptors (Adr(2R)) was evaluated using quantitative radioautography within NTS subnuclei and using neuronal culture of normotensive (WKY) and spontaneously hypertensive rats (SHR). Radioautography was used in a saturation experiment to measure Adr2R binding parameters (B(max), K(d)) In the presence of 3 different concentrations of N(6)-cyclopentyladenosine (CPA), an A(1R) agonist. Neuronal culture confirmed our radioautographic results. [(3)H]RX821002, an Adr(2R) antagonist, was used as a ligand for both approaches. The dorsomedial/dorsolateral subnucleus of WKY showed an increase in B(max) values (21%) Induced by 10 nmol/L of CPA. However, the subpostremal subnucleus showed a decrease in Kd values (24%) induced by 10 nmol/L of CPA. SHR showed the same pattern of changes as WKY within the same subnuclei; however, the modulatory effect of CPA was induced by I nmol/L (increased B(max), 17%; decreased K(d), 26%). Cell culture confirmed these results, because 10(-5) and 10(-7) mol/L of CPA promoted an Increase in [3H]RX821002 binding of WKY (53%) and SHR cells (48%), respectively. DPCPX, an AIR antagonist, was used to block the modulatory effect promoted by CPA with respect to Adr2R binding. In conclusion, our study shows for the first time an interaction between A(1R) that increases the binding of Adr2R within specific subnuclei of the NTS. This may be important In understanding the complex autonomic response induced by adenosine within the NTS. In addition, changes in interactions between receptors might be relevant to understanding the development of hypertension. (Hypertens Res 2008; 31: 2177-2186)

A physiological role of the adenosine A3 receptor: Sustained cardioprotection

Adenosine released during cardiac ischemia exerts a potent, protective effect in the heart. A newly recognized adenosine receptor, the A3 subtype, is expressed on the cardiac ventricular cell, and its activation protects the ventricular heart cell against injury during a subsequent exposure to ischemia. A cultured chicken ventricular myocyte model was used to investigate the cardioprotective role of a novel adenosine A3 receptor. The protection mediated by prior activation of A3 receptors exhibits a significantly longer duration than that produced by activation of the adenosine A1 receptor. Prior exposure of the myocytes to brief ischemia also protected them against injury sustained during a subsequent exposure to prolonged ischemia. The adenosine A3 receptor-selective antagonist 3-ethyl 5-benzyl-2-methyl-6-phenyl-4-phenylethynyl-1,4-(±)-dihydropyridine-3,5-dicarboxylate (MRS1191) caused a biphasic inhibition of the protective effect of the brief ischemia. The concomitant presence of the A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) converted the MRS1191-induced dose inhibition curve to a monophasic one. The combined presence of both antagonists abolished the protective effect induced by the brief ischemia. Thus, activation of both A1 and A3 receptors is required to mediate the cardioprotective effect of the brief ischemia. Cardiac atrial cells lack native A3 receptors and exhibit a shorter duration of cardioprotection than do ventricular cells. Transfection of atrial cells with cDNA encoding the human adenosine A3 receptor causes a sustained A3 agonist-mediated cardioprotection. The study indicates that cardiac adenosine A3 receptor mediates a sustained cardioprotective function and represents a new cardiac therapeutic target.

Muscarinic stimulation of synaptic activity by protein kinase C is inhibited by adenosine in cultured hippocampal neurons

We have studied the effect of the cholinergic agonist carbachol on the spontaneous release of glutamate in cultured rat hippocampal cells. Spontaneous excitatory postsynaptic currents (sEPSCs) through glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type channels were recorded by means of the patch-clamp technique. Carbachol increased the frequency of sEPSCs in a concentration-dependent manner. The kinetic properties of the sEPSCs and the amplitude distribution histograms were not affected by carbachol, arguing for a presynaptic site of action. This was confirmed by measuring the turnover of the synaptic vesicular pool by means of the fluorescent dye FM 1–43. The carbachol-induced increase in sEPSC frequency was not mimicked by nicotine, but could be blocked by atropine or by pirenzepine, a muscarinic cholinergic receptor subtype M1 antagonist. Intracellular Ca2+ signals recorded with the fluorescent probe Fluo-3 indicated that carbachol transiently increased intracellular Ca2+ concentration. Since, however, carbachol still enhanced the sEPSC frequency in bis(2-aminophenoxy)ethane-N,N,N′,N′-tetra-acetate-loaded cells, this effect could not be attributed to the rise in intracellular Ca2+ concentration. On the other hand, the protein kinase inhibitor staurosporine as well as a down-regulation of protein kinase C by prolonged treatment of the cells with 4β-phorbol 12-myristate 13-acetate inhibited the carbachol effect. This argues for an involvement of protein kinase C in presynaptic regulation of spontaneous glutamate release. Adenosine, which inhibits synaptic transmission, suppressed the carbachol-induced stimulation of sEPSCs by a G protein-dependent mechanism activated by presynaptic A1-receptors.

Functional significance of adenosine in carotid body chemosensory activity in control and chronically hypoxic animals

ABSTRACT: Carotid bodies (CB) are peripheral chemoreceptor organs sensing changes in arterial blood O2, CO2 and pH levels. Hypoxia and acidosis or hypercapnia activates CB chemoreceptor cells, which respond by releasing neurotransmitters in order to increase the action potential frequency in their sensory nerve, the carotid sinus nerve (CSN). CSN activity is integrated in the brainstem to induce a fan of cardiorespiratory reflex responses, aimed at normalising the altered blood gases. Exogenously applied adenosine (Ado) increases CSN chemosensory activity inducing hyperventilation through activation of A2 receptors. The importance of the effects of adenosine in chemoreception was reinforced by data obtained in humans, in which the intravenous infusion of Ado causes hyperventilation and dyspnoea, an effect that has been attributed to the activation of CB because Ado does not cross blood-brain barrier and because the ventilatory effects are higher the closer to the CB it is injected. The present work was performed in order to establish the functional significance of adenosine in chemoreception at the carotid body in control and chronically hypoxic rats. To achieve this objective we investigated: 1) The release of adenosine from a rat carotid body in vitro preparation in response to moderate hypoxia and the specificity of this release. We also investigated the metabolic pathways of adenosine production and release in the organ in normoxia and hypoxia; 2) The modulation of adenosine/ATP release from rat carotid body chemoreceptor cells by nicotinic ACh receptors; 3) The effects of caffeine on peripheral control of breathing and the identity of the adenosine receptors involved in adenosine and caffeine effects on carotid body chemoreceptors; 4) The interactions between dopamine D2 receptors and adenosine A2B receptors that modulate the release of catecholamines (CA) from the rat carotid body; 5) The effect of chronic caffeine intake i.e. the continuous blockage of adenosine receptors thereby simulating a caffeine dependence, on the carotid body function in control and chronically hypoxic rats. The methodologies used in this work included: molecular biology techniques (e.g. immunocytochemistry and western-blot), biochemical techniques (e.g. neurotransmitter quantification by HPLC, bioluminescence and radioisotopic methods), electrophysiological techniques (e.g. action potential recordings) and ventilatory recordings using whole-body plethysmography. It was observed that: 1) CB chemoreceptor sensitivity to hypoxia could be related to its low threshold for the release of adenosine because moderate acute hypoxia (10% O2) increased adenosine concentrations released from the CB by 44% but was not a strong enough stimulus to evoke adenosine release from superior cervical ganglia and arterial tissue; 2) Acetylcholine (ACh) modulates the release of adenosine/5’-adenosine triphosphate (ATP) from CB in moderate hypoxia through the activation of nicotinic receptors with α4 and ß2 receptor subunits, suggesting that the excitatory role of ACh in chemosensory activity includes indirect activation of purinergic receptors by adenosine and ATP, which strongly supports the hypothesis that ATP/adenosine are important mediators in chemotransduction; 3) adenosine increases the release of CA from rat CB chemoreceptor cells via A2B receptors; 4) the inhibitory effects of caffeine on CB chemoreceptors are mediated by antagonism of postsynaptic A2A and presynaptic A2B adenosine receptors indicating that chemosensory activity elicited by hypoxia is controlled by adenosine; 5) The release of CA from rat CB chemoreceptor cells is modulated by adenosine through an antagonistic interaction between A2B and D2 receptors, for the first time herein described; 6) chronic caffeine treatment did not significantly alter the basal function of CB in normoxic rats assessed as the dynamics of their neurotransmitters, dopamine, ATP and adenosine, and the CSN chemosensory activity. In contrast, the responses to hypoxia in these animals were facilitated by chronic caffeine intake because it increased the ventilatory response, slightly increased CSN chemosensory activity and increased dopamine (DA) and ATP release; 7) In comparison with normoxic rats, chronically hypoxic rats exhibited an increase in several parameters: ventilatory hypoxic response; basal and hypoxic CSN activity; tyrosine hydroxylase expression, CA content, synthesis and release; basal and hypoxic adenosine release; and in contrast a normal basal release and diminished hypoxia-induced ATP release; 8) Finally, in contrast to chronically hypoxic rats, chronic caffeine treatment did not alter the basal CSN chemosensory activity. Nevertheless, the responses to mild and intense hypoxia, and hypercapnia, were diminished. This inhibitory effect of chronic caffeine in CB output is compensated by central mechanisms, as the minute ventilation parameter in basal conditions and in response to acute hypoxic challenges remained unaltered in rats exposed to chronic hypoxia. We can conclude that adenosine both in acute and chronically hypoxic conditions have an excitatory role in the CB chemosensory activity, acting directly on adenosine A2A receptors present postsynaptically in CSN, and acting presynaptically via A2B receptors controlling the release of dopamine in chemoreceptor cells. We suggest that A2B -D2 adenosine / dopamine interactions at the CB could explain the increase in CA metabolism caused by chronic ingestion of caffeine during chronic hypoxia. It was also concluded that adenosine facilitates CB sensitisation to chronic hypoxia although this effect is further compensated at the central nervous system.-------- RESUMO: Os corpos carotídeos (CB) são pequenos orgãos emparelhados localizados na bifurcação da artéria carótida comum. Estes órgãos são sensíveis a variações na PaO2, PaCO2, pH e temperatura sendo responsáveis pela hiperventilação que ocorre em resposta à hipóxia, contribuindo também para a hiperventilação que acompanha a acidose metabólica e respiratória. As células quimiorreceptoras (tipo I ou glómicas) do corpo carotídeo respondem às variações de gases arteriais libertando neurotransmissores que activam as terminações sensitivas do nervo do seio carotídeo (CSN) conduzindo a informação ao centro respiratório central. Está ainda por esclarecer qual o neurotransmissor (ou os neurotransmissores) responsável pela sinalização hipóxica no corpo carotídeo. A adenosina é um neurotransmissor excitatório no CB que aumenta a actividade eléctrica do CSN induzindo a hiperventilação através da activação de receptores A2. A importância destes efeitos da adenosina na quimiorrecepção, descritos em ratos e gatos, foi reforçada por resultados obtidos em voluntários saudáveis onde a infusão intravenosa de adenosina em induz hiperventilação e dispneia, efeito atribuído a uma activação do CB uma vez que a adenosina não atravessa a barreira hemato-encefálica e o efeito é quanto maior quanto mais perto do CB for a administração de adenosina. O presente trabalho foi realizado com o objectivo de esclarecer qual o significado funcional da adenosina na quimiorrecepção no CB em animais controlo e em animais submetidos a hipoxia crónica mantida. Para alcançar este objectivo investigou-se: 1) o efeito da hipóxia moderada sobre a libertação de adenosina numa preparação in vitro de CB e a especificidade desta mesma libertação comparativamente com outros tecidos não quimiossensitivos, assim como as vias metabólicas de produção e libertação de adenosina no CB em normoxia e hipóxia; 2) a modulação da libertação de adenosina/ATP das células quimiorreceptoras do CB por receptores nicotínicos de ACh; 3) os efeitos da cafeína no controlo periférico da ventilação e a identidade dos receptores de adenosina envolvidos nos efeitos da adenosina e da cafeína nos quimiorreceptores do CB; 4) as interacções entre os receptores D2 de dopamina e os receptores A2B de adenosina que modulam a libertação de catecolaminas (CA) no CB de rato e; 5) o efeito da ingestão crónica de cafeína, isto é, o contínuo bloqueio e dos receptores de adenosina, simulando assim o consumo crónico da cafeína, tal como ocorre na população humana mundial e principalmente no ocidente, na função do corpo carotídeo em ratos controlo e em ratos submetidos a hipoxia crónica. Os métodos utilizados neste trabalho incluíram: técnicas de biologia molecular como imunocitoquímica e western-blot; técnicas bioquímicas, tais como a quantificação de neurotransmissores por HPLC, bioluminescência e métodos radioisotópicos; técnicas electrofisiológicas como o registro de potenciais eléctricos do nervo do seio carotídeo in vitro; e registros ventilatórios in vivo em animais não anestesiados e em livre movimento (pletismografia). Observou-se que: 1) a especificidade dos quimiorreceptores do CB como sensores de O2 está correlacionada com o baixo limiar de libertação de adenosina em resposta à hipóxia dado que a libertação de adenosina do CB aumenta 44% em resposta a uma hipóxia moderada (10% O2), que no entanto não é um estímulo suficientemente intenso para evocar a libertação de adenosina do gânglio cervical superior ou do tecido arterial. Observou-se também que aproximadamente 40% da adenosina libertada pelo CB provém do catabolismo extracelular do ATP quer em normóxia quer em hipóxia moderada, sendo que PO2 reduzidas induzem a libertação de adenosina via activação do sistema de transporte equilibrativo ENT1. 2) a ACh modula a libertação de adenosina /ATP do CB em resposta à hipoxia moderada sugerindo que o papel excitatório da ACh na actividade quimiossensora inclui a activação indirecta de receptores purinérgicos pela adenosina e ATP, indicando que a adenosina e o ATP poderiam actuar como mediadores importantes no processo de quimiotransducção uma vez que: a) a activação dos receptores nicotínicos de ACh no CB em normóxia estimula a libertação de adenosina (max 36%) provindo aparentemente da degradação extracelular do ATP. b) a caracterização farmacológica dos receptores nicotínicos de ACh envolvidos na estimulação da libertação de adenosina do CB revelou que os receptores nicotínicos de ACh envolvidos são constituídos por subunidades α4ß2. 3) a adenosina modula a libertação de catecolaminas das células quimiorreceptoras do CB através de receptores de adenosina A2B dado que: a)a cafeína, um antagonista não selectivo dos receptores de adenosina, inibiu a libertação de CA quer em normóxia quer em resposta a estímulos de baixa intensidade sendo ineficaz na libertação induzida por estímulos de intensidade superior; b) o DPCPX e do MRS1754 mimetizaram os efeitos da cafeína no CB sendo o SCH58621 incapaz de induzir a libertação de CA indicando que os efeitos da cafeína seriam mediados por receptores A2B de adenosina cuja presença nas células quimiorreceptoras do CB demonstramos por imunocitoquímica. 4) a aplicação aguda de cafeína inibiu em 52% a actividade quimiossensora do CSN induzida pela hipóxia sendo este efeito mediado respectivamente por receptores de adenosina A2A pós-sinápticos e A2B pré-sinápticos indicando que a actividade quimiossensora induzida pela hipóxia é controlada pela adenosina. 5) existe uma interacção entre os receptores A2B e D2 que controla a libertação de CA do corpo carotídeo de rato uma vez que: a) os antagonistas dos receptores D2, domperidona e haloperidol, aumentaram a libertação basal e evocada de CA das células quimiorreceptoras confirmando a presença de autorreceptores D2 no CB de rato que controlam a libertação de CA através de um mecanismo de feed-back negativo. b) o sulpiride, um antagonista dos receptores D2, aumentou a libertação de CA das células quimiorreceptoras revertendo o efeito inibitório da cafeína sobre esta mesma libertação; c) a propilnorapomorfina, um agonista D2 inibiu a libertação basal e evocada de CA sendo este efeito revertido pela NECA, um agonista dos receptores A2B. O facto de a NECA potenciar o efeito do haloperidol na libertação de CA sugere que a interacção entre os receptores D2 e A2B poderia também ocorrer ao nível de segundos mensageiros, como o cAMP. 6) a ingestão crónica de cafeína em ratos controlo (normóxicos) não alterou significativamente a função basal do CB medida como a dinâmica dos seus neurotransmissores, dopamina, ATP e adenosina e como actividade quimiossensora do CSN. Contrariamente aos efeitos basais, a ingestão crónica de cafeína facilitou a resposta à hipóxia, dado que aumentou o efeito no volume minuto respiratórioapresentando-se também uma clara tendência para aumentar a actividade quimiossensora do CSN e aumentar a libertação de ATP e dopamina.7) após um período de 15 dias de hipóxia crónica era evidente o fenómeno de aclimatização dado que as respostas ventilatórias à hipóxia se encontram aumentadas, assim como a actividade quimiossensora do CSN basal e induzida pela hipóxia. As alterações observadas no metabolismo da dopamina, assim como na libertação basal de dopamina e de adenosina poderiam contribuir para a aclimatização durante a hipoxia crónica. A libertação aumentada de adenosina em resposta à hipóxia aguda em ratos hipóxicos crónicos sugere um papel da adenosina na manutenção/aumento das respostas ventilatórias à hipóxia aguda durante a hipóxia crónica. Observou-se também que a libertação de ATP induzida pela hipóxia aguda se encontra diminuída em hipóxia crónica, contudo a ingestão crónica de cafeína reverteu este efeito para valores similares aos valores controlo, sugerindo que a adenosina possa modular a libertação de ATP em hipóxia crónica. 8) a ingestão crónica de cafeína em ratos hipóxicos crónicos induziu o aumento do metabolismo de CA no CB, medido como expressão de tirosina hidroxilase, conteúdo, síntese e libertação de CA. 9) a ingestão crónica de cafeína não provocou quaisquer alterações na actividade quimiossensora do CSN em ratos hipóxicos crónicos no entanto, as respostas do CSN à hipóxia aguda intensa e moderada e à hipercapnia encontram-se diminuídas. Este efeito inibitório que provém da ingestão crónica de cafeína parece ser compensado ao nível dos quimiorreceptores centrais dado que os parâmetros ventilatórios em condições basais e em resposta à hipoxia aguda não se encontram modificados em ratos expostos durante 15 dias a uma atmosfera hipóxica. Resumindo podemos assim concluir que a adenosina quer em situações de hipoxia aguda quer em condições de hipoxia crónica tem um papel excitatório na actividade quimiossensora do CB actuando directamente nos receptores A2A presentes pós-sinapticamente no CSN, assim como facilitando a libertação de dopamina pré-sinapticamente via receptores A2B presentes nas células quimiorreceptoras. A interacção negativa entre os receptores A2B e D2 observadas nas células quimiorreceptoras do CB poderia explicar o aumento do metabolismo de CA observado após a ingestão crónica de cafeína em animais hipóxicos. Conclui-se ainda que durante a aclimatização à hipóxia a acção inibitória da cafeína, em termos de resposta ventilatória, mediada pelos quimiorreceptores periféricos é compensada pelos efeitos excitatórios desta xantina ao nível do quimiorreceptores centrais.------- RESUMEN Los cuerpos carotídeos (CB) son órganos emparejados que están localizados en la bifurcación de la arteria carótida común. Estos órganos son sensibles a variaciones en la PaO2, en la PaCO2, pH y temperatura siendo responsables de la hiperventilación que ocurre en respuesta a la hipoxia, contribuyendo también a la hiperventilación que acompaña a la acidosis metabólica y respiratoria. Las células quimiorreceptoras (tipo I o glómicas) del cuerpo carotídeo responden a las variaciones de gases arteriales liberando neurotransmissores que activan las terminaciones sensitivas del nervio del seno carotídeo (CSN) llevando la información al centro respiratorio central. Todavía esta por clarificar cual el neurotransmisor (o neurotransmisores) responsable por la señalización hipóxica en el CB. La adenosina es un neurotransmisor excitatório en el CB ya que aumenta la actividad del CSN e induce la hiperventilación a través de la activación de receptores de adenosina del subtipo A2. La importancia de estos efectos de la adenosina en la quimiorrecepción, descritos en ratas y gatos, ha sido fuertemente reforzada por resultados obtenidos en voluntarios sanos en los que la infusión intravenosa de adenosina induce hiperventilación y dispnea, efectos estés que han sido atribuidos a una activación del CB ya que la adenosina no cruza la barrera hemato-encefalica y el efecto es tanto más grande cuanto más cercana del CB es la administración. Este trabajo ha sido realizado con el objetivo de investigar cual el significado funcional de la adenosina en la quimiorrecepción en el CB en animales controlo y en animales sometidos a hipoxia crónica sostenida. Para alcanzar este objetivo se ha estudiado: 1) el efecto de la hipoxia moderada en la liberación de adenosina en una preparación in vitro de CB y la especificidad de esta liberación en comparación con otros tejidos no-quimiosensitivos, así como las vías metabólicas de producción y liberación de adenosina del órgano en normoxia y hipoxia; 2) la modulación de la liberación de adenosina/ATP de las células quimiorreceptoras del CB por receptores nicotínicos de ACh; 3) los efectos de la cafeína en el controlo periférico de la ventilación y la identidad de los receptores de adenosina involucrados en los efectos de la adenosina y cafeína en los quimiorreceptores del CB; 4) las interacciones entre los receptores D2 de dopamina y los receptores A2B de adenosina que modulan la liberación de catecolaminas (CA) en el CB de rata y; 5) el efecto de la ingestión crónica de cafeína, es decir, el bloqueo sostenido de los receptores de adenosina, simulando la dependencia de cafeína observada en la populación mundial del occidente, en la función del CB en ratas controlo y sometidas a hipoxia crónica sostenida. Los métodos utilizados en este trabajo incluirán: técnicas de biología molecular como imunocitoquímica y western-blot; técnicas bioquímicas, tales como la cuantificación de neurotransmissores por HPLC, bioluminescencia y métodos radioisotópicos; técnicas electrofisiológicas como el registro de potenciales eléctricos del nervio do seno carotídeo in vitro; y registros ventilatórios in vivo en animales no anestesiados y en libre movimiento (pletismografia). Se observó que: 1) la sensibilidad de los quimiorreceptores de CB esta correlacionada con un bajo umbral de liberación de adenosina en respuesta a la hipoxia ya que en respuesta a una hipoxia moderada (10% O2) la liberación de adenosina en el CB aumenta un 44%, sin embargo esta PaO2 no es un estimulo suficientemente fuerte para inducir la liberación de adenosina del ganglio cervical superior o del tejido arterial; se observó también que aproximadamente 40% de la adenosina liberada del CB proviene del catabolismo extracelular del ATP en normoxia y en hipoxia moderada, y que bajas PO2 inducen la liberación de adenosina vía activación del sistema de transporte equilibrativo ENT1. 2) la ACh modula la liberación de adenosina /ATP del CB en respuesta a la hipóxia moderada lo que sugiere que el papel excitatório de la ACh en la actividad quimiosensora incluye la activación indirecta de receptores purinérgicos por la adenosina y el ATP, indicando que la adenosina y el ATP pueden actuar como mediadores importantes en el proceso de quimiotransducción ya que: a) la activación de los receptores nicotínicos de ACh en el CB en normoxia estimula la liberación de adenosina (max 36%) que aparentemente proviene de la degradación extracelular del ATP. Se observó también que este aumento de adenosina en el CB en hipoxia ha sido antagonizado parcialmente por antagonistas de estos mismos receptores; b) la caracterización farmacológica de los receptores nicotínicos de ACh involucrados en la estimulación de la liberación de adenosina del CB ha revelado que los receptores nicotínicos de ACh involucrados son constituidos por sub-unidades α4ß2. 3) la adenosina modula la liberación de CA de las células quimiorreceptoras del CB a través de receptores de adenosina A2B ya que: a) la cafeína, un antagonista no selectivo de los receptores de adenosina, ha inhibido la liberación de CA en normoxia y en respuesta a estímulos de baja intensidad siendo ineficaz en la liberación inducida por estímulos de intensidad superior; b) el DPCPX y el MRS1754 ha mimetizado los efectos de la cafeína en el CB y el SCH58621 ha sido incapaz de inducir la liberación de CA lo que sugiere que los efectos de la cafeína son mediados por receptores A2B de adenosina que están localizados pré-sinapticamente en las células quimiorreceptoras del CB. 4) la aplicación aguda de cafeína ha inhibido en 52% la actividad quimiosensora del CSN inducida por la hipoxia siendo este efecto mediado respectivamente por receptores de adenosina A2A pós-sinápticos y A2B pré-sinápticos lo que indica que la actividad quimiosensora inducida por la hipoxia es controlada por la adenosina. 5) existe una interacción entre los receptores A2B y D2 que controla la liberación de CA del CB de rata ya que: a) el sulpiride, un antagonista de los receptores D2, ha aumentado la liberación de CA de las células quimiorreceptoras revertiendo el efecto inhibitorio de la cafeína sobre esta misma liberación; b) los antagonistas de los receptores D2, domperidona y haloperidol, han aumentado la liberación basal e evocada de CA de las células quimiorreceptoras confirmando la presencia de autorreceptores D2 en el CB de rata que controlan la liberación de CA a través de un mecanismo de feed-back negativo; c) la propilnorapomorfina, un agonista D2, ha inhibido la liberación basal e evocada de CA sendo este efecto revertido por la NECA, un agonista de los receptores A2B. Ya que la NECA potencia el efecto del haloperidol en la liberación de CA la interacción entre los D2 y A2B puede también ocurrir al nivel de segundos mensajeros, como el cAMP. 6) la ingestión crónica de cafeína en ratas controlo (normóxicas) no ha cambiado significativamente la función basal del CB medida como la dinámica de sus neurotransmisores, dopamina, ATP y adenosina y como actividad quimiosensora del CSN. Al revés de lo que pasa con los efectos básales, la ingestión crónica de cafeína facilitó la respuesta a la hipóxia, ya que ha aumentado la respuesta ventilatória medida como volumen minuto presentando también una clara tendencia para aumentar la actividad quimiosensora del CSN y aumentar la liberación de ATP y dopamina. 7. Después de un período de 15 días de hipoxia crónica se puede observar el fenómeno de climatización ya que las respuestas ventilatórias a la hipoxia están aumentadas, así como la actividad quimiosensora del CSN basal e inducida por la hipoxia. Los cambios observados en el metabolismo de la dopamina, así como en la liberación basal de dopamina y de adenosina podrían contribuir para la climatización en hipoxia crónica. El aumento en la liberación de adenosina en respuesta a la hipoxia aguda en ratas sometidas a hipoxia crónica sugiere un papel para la adenosina en el mantenimiento/aumento de las respuestas ventilatórias a la hipoxia aguda en hipoxia crónica sostenida. Se ha observado también que la liberación de ATP inducida por la hipoxia aguda está disminuida en hipoxia crónica y que la ingestión crónica de cafeína reverte este efecto para valores similares a los valores controlo, sugiriendo que la adenosina podría modular la liberación de ATP en hipoxia crónica. 8. la ingestión crónica de cafeína ha inducido el aumento del metabolismo de CA en el CB en ratas hipóxicas crónicas, medido como expresión de la tirosina hidroxilase, contenido, síntesis y liberación de CA. 9. la ingestión crónica de cafeína no ha inducido cambios en la actividad quimiosensora del CSN en ratas hipóxicas crónicas sin embargo las respuestas do CSN a una hipoxia intensa y moderada y a la hipercapnia están disminuidas. Este efecto inhibitorio que es debido a la ingestión crónica de cafeína es compensado al nivel de los quimiorreceptores centrales ya que los parámetros ventilatórios en condiciones básales y en respuesta a la hipoxia aguda no están modificados en ratas expuestas durante 15 días a una atmósfera hipóxica. Resumiendo se puede concluir que la adenosina en situaciones de hipoxia aguda así como en hipoxia crónica tiene un papel excitatório en la actividad quimiosensora del CB actuando directamente en los receptores A2A localizados pós-sinapticamente en el CSN, así como controlando la liberación de dopamina pré-sinaptica vía receptores A2B localizados en las células quimiorreceptoras. Las interacciones entre los receptores A2B y D2 observadas en las células quimiorreceptoras del CB podrían explicar el aumento del metabolismo de CA observado después de la ingestión crónica de cafeína en animales hipóxicos. Por fin, pero no menos importante se puede concluir que durante la climatización a la hipoxia la acción inhibitoria de la cafeína, medida como respuesta ventilatória, mediada por los quimiorreceptores periféricos es compensada por los efectos excitatórios de esta xantina al nivel de los quimiorreceptores centrales.

Adenosine A2A receptor gene expression in the normal striatum and after 6-OH-dopamine lesion

Adenosine A2A receptors are present on enkephalinergic medium sized striatal neurons in the rat and have an important function in the modulation of striatal output. In order to establish more accurately whether adenosine transmission is a generalized phenomenon in mammalian striatum we compared the A2A R expression in the mouse, rat, cat and human striatum. Secondly we compared the modulation of enkephalin gene expression and A2A receptor gene expression in rat striatal neurons after 6-OH-dopamine lesion of the substantia nigra. Hybridization histochemistry was performed with a 35S-labelled radioactive oligonucleotide probe. The results showed high expression of A2A adenosine receptor genes only in the medium-sized cells of the striatum in all examined species. In the rat striatum, expression of A2A receptors was not significantly altered after lesion of the dopaminergic pathways with 6-OH-dopamine even though enkephalin gene expression was up-regulated. The absence of a change in A2A receptor gene expression after 6-OH-dopamine treatment speaks against a dependency on dopaminergic innervation. The maintained inhibitory function of A2A R on motor activity in spite of dopamine depletion could be partly responsible for the depression of locomotor activity observed in basal ganglia disorders such as Parkinson's disease.

Expression of adenosine A2a receptor gene in rat dorsal root and autonomic ganglia

The adenosine A2a receptors (A2aR) play an important role in the purinergic mediated neuromodulation. The presence of A2aR in the brain is well established. In contrast, little is known about their expression in the periphery. The purpose of this study was to investigate the expression of A2aR gene in the autonomic (otic, sphenopalatine, ciliary, cervical superior ganglia and carotid body) and in the dorsal root ganglia of normal rat. Hybridization histochemistry with S35-labelled radioactive oligonucleotide probes was used. An expression of A2aR gene was found in the large neuronal cells of the rat dorsal root ganglia. The satellite cells showed no expression of A2aR gene. In the superior cervical ganglion, isolated ganglion cells expressed A2aR. In the carotid body clusters of cells with a strong A2aR gene expression were found. In contrast, the ciliary and otic ganglia did not expressed A2aR gene, and only few small sized A2aR expressing cells were demonstrated in the sphenopalatine ganglion. The discrete distribution of A2aR gene expression in the peripheral nervous system speaks for a role of this receptor in the purinergic modulation of sensory information as well as in the sympathetic nervous system.

Activation of Trk neurotrophin receptors in the absence of neurotrophins

Neurotrophins regulate neuronal cell survival and synaptic plasticity through activation of Trk receptor tyrosine kinases. Binding of neurotrophins to Trk receptors results in receptor autophosphorylation and downstream phosphorylation cascades. Here, we describe an approach to use small molecule agonists to transactivate Trk neurotrophin receptors. Activation of TrkA receptors in PC12 cells and TrkB in hippocampal neurons was observed after treatment with adenosine, a neuromodulator that acts through G protein-coupled receptors. These effects were reproduced by using the adenosine agonist CGS 21680 and were counteracted with the antagonist ZM 241385, indicating that this transactivation event by adenosine involves adenosine 2A receptors. The increase in Trk activity could be inhibited by the use of the Src family-specific inhibitor, PP1, or K252a, an inhibitor of Trk receptors. In contrast to other G protein-coupled receptor transactivation events, adenosine used Trk receptor signaling with a longer time course. Moreover, adenosine activated phosphatidylinositol 3-kinase/Akt through a Trk-dependent mechanism that resulted in increased cell survival after nerve growth factor or brain-derived neurotrophic factor withdrawal. Therefore, adenosine acting through the A2A receptors exerts a trophic effect through the engagement of Trk receptors. These results provide an explanation for neuroprotective actions of adenosine through a unique signaling mechanism and raise the possibility that small molecules may be used to elicit neurotrophic effects for the treatment of neurodegenerative diseases.

Imaging Neuroinflammation in Progressive Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system CNS), where inflammation and neurodegeneration lead to irreversible neuronal damage. In MS, a dysfunctional immune system causes auto‐reactive lymphocytes to migrate into CNS where they initiate an inflammatory cascade leading to focal demyelination, axonal degeneration and neuronal loss. One of the hallmarks of neuronal injury and neuroinflammation is the activation of microglia. Activated microglia are found not only in the focal inflammatory lesions, but also diffusely in the normal‐appearing white matter (NAWM), especially in progressive MS. The purine base, adenosine is a ubiquitous neuromodulator in the CNS and also participates in the regulation of inflammation. The effect of adenosine mediated via adenosine A2A receptors has been linked to microglial activation, whereas modulating A2A receptors may exert neuroprotective effects. In the majority of patients, MS presents with a relapsing disease course, later advancing to a progressive phase characterised by a worsening, irreversible disability. Disease modifying treatments can reduce the severity and progression in relapsing MS, but no efficient treatment exists for progressive MS. The aim of this research was to investigate the prevalence of adenosine A2A receptors and activated microglia in progressive MS by using in vivo positron emission tomography (PET) imaging and [11C]TMSX and [11C](R)‐PK11195 radioligands. Magnetic resonance imaging (MRI) with diffusion tensor imaging (DTI) was performed to evaluate structural brain damage. Non‐invasive input function methods were also developed for the analyses of [11C]TMSX PET data. Finally, histopathological correlates of [11C](R)‐PK11195 radioligand binding related to chronic MS lesions were investigated in post‐mortem samples of progressive MS brain using autoradiography and immunohistochemistry. [11C]TMSX binding to A2A receptors was increased in NAWM of secondary progressive MS (SPMS) patients when compared to healthy controls, and this correlated to more severe atrophy in MRI and white matter disintegration (reduced fractional anisotropy, FA) in DTI. The non‐invasive input function methods appeared as feasible options for brain [11C]TMSX images obviating arterial blood sampling. [11C](R)‐PK11195 uptake was increased in the NAWM of SPMS patients when compared to patients with relapsing MS and healthy controls. Higher [11C](R)‐PK11195 binding in NAWM and total perilesional area of T1 hypointense lesions was associated with more severe clinical disability, increased brain atrophy, higher lesion load and reduced FA in NAWM in the MS patients. In autoradiography, increased perilesional [11C](R)‐PK11195 uptake was associated with increased microglial activation identified using immunohistochemistry. In conclusion, brain [11C]TMSX PET imaging holds promise in the evaluation of diffuse neuroinflammation in progressive MS. Being a marker of microglial activation, [11C](R)‐ PK11195 PET imaging could possibly be used as a surrogate biomarker in the evaluation of the neuroinflammatory burden and clinical disease severity in progressive MS.

Advanced Protein Modeling Method: Benchmarking and Applications in Computer-Aided Drug Discovery

Development of homology modeling methods will remain an area of active research. These methods aim to develop and model increasingly accurate three-dimensional structures of yet uncrystallized therapeutically relevant proteins e.g. Class A G-Protein Coupled Receptors. Incorporating protein flexibility is one way to achieve this goal. Here, I will discuss the enhancement and validation of the ligand-steered modeling, originally developed by Dr. Claudio Cavasotto, via cross modeling of the newly crystallized GPCR structures. This method uses known ligands and known experimental information to optimize relevant protein binding sites by incorporating protein flexibility. The ligand-steered models were able to model, reasonably reproduce binding sites and the co-crystallized native ligand poses of the β2 adrenergic and Adenosine 2A receptors using a single template structure. They also performed better than the choice of template, and crude models in a small scale high-throughput docking experiments and compound selectivity studies. Next, the application of this method to develop high-quality homology models of Cannabinoid Receptor 2, an emerging non-psychotic pain management target, is discussed. These models were validated by their ability to rationalize structure activity relationship data of two, inverse agonist and agonist, series of compounds. The method was also applied to improve the virtual screening performance of the β2 adrenergic crystal structure by optimizing the binding site using β2 specific compounds. These results show the feasibility of optimizing only the pharmacologically relevant protein binding sites and applicability to structure-based drug design projects.